Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting
November 25 2020 - 7:00AM
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a
clinical stage immuno-oncology company developing innovative
therapies for the treatment of cancer, today announced the
presentation of clinical data at the upcoming American Society of
Hematology (ASH) Annual Meeting, which is being held virtually from
December 5-8, 2020.
TTI-622:
Poster Presentation, Publication
Number 1191Investigational CD47-Blocker
TTI-622 Shows Single-Agent Activity in Patients with Advanced
Relapsed or Refractory Lymphoma: Update from the Ongoing
First-in-Human Dose Escalation StudyPresenter: Krish Patel, M.D.,
Center for Blood Disorders and Stem Cell Transplantation, Swedish
Cancer Institute, Seattle, WASession: 626. Aggressive Lymphoma
(Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin
Lymphomas)-Results from Prospective Clinical Trials: Poster IDate:
Saturday, December 5, 2020; available from 10:00AM EST
TTI-621: Oral
Presentation,
Publication
Number
646Updates from Ongoing, First-in-Human Phase 1
Dose Escalation and Expansion Study of TTI-621, a Novel Biologic
Targeting CD47, in Patients with Relapsed or Refractory Hematologic
MalignanciesPresenter: Steven M. Horwitz, M.D., Department of
Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center,
New York, NYSession: 624. Hodgkin Lymphoma and T/NK Cell
Lymphoma—Clinical Studies: Immunotherapy in T/NK Cell LymphomaDate:
Monday, December 7, 2020; Presentation at 3:00PM EST
The presentations will be available in the
Events & Presentations section of Trillium’s website once
released by the American Society of Hematology.
Trillium will host a conference call on Monday,
December 7th at 4:30PM EST.
International Dial-In Number: +1
236-389-2162Conference ID: 3169183
Webcast link:
https://event.on24.com/wcc/r/2862177/A91BDB88D738527918C13E289B26CED7
About Trillium
Therapeutics Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
company’s two clinical programs, TTI-621 and TTI-622, target
CD47, a “don’t eat me” signal that cancer cells frequently use to
evade the immune system.
For more information visit:
www.trilliumtherapeutics.com
Investor
Relations:James ParsonsChief Financial
OfficerTrillium Therapeutics Inc. 416-595-0627
x232james@trilliumtherapeutics.com www.trilliumtherapeutics.com
Media Relations:Mike BeyerSam
Brown Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Sep 2023 to Sep 2024